esomeprazole / Generic mfg. - LARVOL DELTA

Chemical stability of esomeprazole in biorelevant bicarbonate buffer and an exploratory study for specific degradation products. (PubMed, J Pharm Biomed Anal) - "The putative structures of these degradation products matched the previously reported compounds. These findings suggest that buffer species can influence degradation pathways even under equivalent β and I. Consequently, the use of biorelevant buffer systems is essential for accurate assessments of degradation products."

Journal

Fourteen-and Ten-Day Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Eradication-A Noninferiority, Multicenter, Randomized Controlled Trial. (PubMed, J Gastroenterol Hepatol) - "The eradication rate of the 14-THA group is > 90%, which is not inferior to the current bismuth-containing quadruple regimen, with a favorable safety profile. However, the efficacy of the 10-THA dual therapy is unacceptable."

Head-to-Head • Journal • Infectious Disease

Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases. (PubMed, Medicine (Baltimore)) - "In the use of PPIs, we should pay attention to the occurrence of related adverse reactions, especially the damage to the infection-related adverse effects, monitor the relevant indicators, and take timely intervention measures to ensure the safety of medication."

Adverse events • Journal • Gastrointestinal Disorder • Infectious Disease • Pneumonia • Respiratory Diseases

Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line Helicobacter pylori eradication: a double-blind randomized controlled trial. (PubMed, Lancet Reg Health Am) - P4 | "We compared optimized bismuth quadruple therapy: esomeprazole 40 mg three times a day, amoxicillin 1 gr three times a day, metronidazole 500 mg three times a day, and bismuth subsalicylate 369 mg three times a day for 14 days, and standard triple therapy omeprazole 20 mg twice a day, amoxicillin 1 gr twice a day, and clarithromycin 500 mg twice a day for 14 days in a Chilean population. Optimized bismuth quadruple therapy is a reliable and safe empiric eradication therapy, especially in areas with high clarithromycin resistance. FONDECYT (1230504 AR); ANID-FONDAP (152220002 AR); Horizon 2020 program of European Union (825832 AR); ANID-FONDAP (15130011)."

Journal • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor • CYP2C19

GERD: Heartburn, Gastroesophageal Reflux Disease (clinicaltrials.gov) - P4 | N=160 | Recruiting | Sponsor: Incheon St.Mary's Hospital

New P4 trial • Gastroenterology • Gastroesophageal Reflux Disease

Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib). (PubMed, Cancer Chemother Pharmacol) - No abstract available

Journal

Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Nurix Therapeutics, Inc. | Trial completion date: Mar 2025 ➔ Dec 2025 | Trial primary completion date: Feb 2025 ➔ Nov 2025

Trial completion date • Trial primary completion date

Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment (clinicaltrials.gov) - P4 | N=1248 | Recruiting | Sponsor: Yongquan Shi | Not yet recruiting ➔ Recruiting

Enrollment open • Dyspepsia • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

Randomized Comparison of Vonoprazan-Amoxicillin Dual Therapy Versus Bismuth Quadruple Therapies for Helicobacter pylori Eradication: A Multicenter Trial Evaluating National Centralized Drug Procurement Antibiotics. (PubMed, J Gastroenterol Hepatol) - "This study confirms that 10-day vonoprazan-amoxicillin dual therapy (using National Centralized Drug Procurement antibiotics) demonstrates noninferior efficacy to bismuth quadruple therapy while offering superior safety, better compliance, and the advantage of shorter treatment duration. These findings support its adoption as a first-line regimen for large-scale H. pylori eradication programs."

Journal • Infectious Disease

Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Can Tho University of Medicine and Pharmacy

New trial • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer

Effect of low-dose esomeprazole on headache frequency in migraine patients with Gastritis symptoms: An observational study (EHF-EHC 2025) - "Low-dose esomeprazole may alleviate both gastric and migraine symptoms in patients with comorbid conditions. These findings suggest that PPI dosage could be an important factor in modulating migraine frequency, and that lower doses may reduce the risk of PPI-associated migraine exacerbation."

Clinical • Observational data • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Response to Proton-Pump Inhibitors Therapy in Pediatric Patients With Eosinophilic Esophagitis in Bogotá, Colombia. (PubMed, Can J Gastroenterol Hepatol) - "Being esomeprazole preferred in 88%, with median dose 1.37 mg/kg/day...This is the first study to assess PPI response in Colombian pediatric EoE patients, demonstrating a response rate consistent with existing literature. Histologic evaluation was identified as the most reliable marker of treatment success, underscoring the critical role of histopathological follow-up in this disease."

Journal • Observational data • Retrospective data • Eosinophilia • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • Pediatrics

Proton pump inhibitors and the risk of urolithiasis: A Mendelian randomization study. (PubMed, Medicine (Baltimore)) - "The genome-wide association studies (GWAS) of Omeprazole, Esomeprazole, Lansoprazole, and Rabeprazole medication can be obtained from GWAS catalog. In conclusion, our results suggest a causal relationship of PPIs to UL. For patients requiring antiacid therapy, esomeprazole may be a better option than Rabeprazole, especially in patients with high-risk factors for urolithiasis."

Journal • Renal Calculi • Urolithiasis

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants (clinicaltrials.gov) - P1 | N=63 | Completed | Sponsor: Incyte Corporation | Recruiting ➔ Completed

Trial completion

Bismuth-Based quintuple therapy: a step beyond quadruple regimens in H. Pylori treatment and the impact of patient compliance. (PubMed, BMC Gastroenterol) - "In this study, we demonstrated that bismuth-based quintuple therapy can be used as an alternative to bismuth-based quadruple therapies and other high-risk treatments. However, we also highlighted the critical importance of treatment adherence."

Compliance • Journal • Infectious Disease

Acid-suppression Drugs After Prophylactic Endoscopic Variceal Treatment of Esophagogastric Variceal Bleeding in Cirrhosis (clinicaltrials.gov) - P=N/A | N=210 | Not yet recruiting | Sponsor: General Hospital of Shenyang Military Region

New trial • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Liver Cirrhosis

Development of a Sustainable One-Pot Process for Esomeprazole Production via Enantioselective Iron Catalysis. (PubMed, Chem Pharm Bull (Tokyo)) - "We also speculate that the carboxylic acid additive plays a critical role in activating hydrogen peroxide through heterolytic cleavage and enabling the formation of both mono- and dinuclear iron oxidants. Furthermore, we propose a catalytic mechanism for this enantioselective oxidation reaction."

Journal

Precision therapy guided by genotypic antibiotic resistance for Helicobacter pylori eradication: A prospective, randomized controlled trial. (PubMed, World J Gastroenterol) - "G-AST-guided therapy yielded higher eradication rates than empirical BQT in first-line H. pylori treatment without increasing adverse events, supporting the clinical utility of individualized, resistance-based therapy."

Clinical • Journal • Infectious Disease

Class effects of proton pump inhibitors in preventing oxaliplatin-induced peripheral neurotoxicity. (PubMed, J Pharmacol Sci) - "Basic research has revealed that omeprazole, a proton pump inhibitor (PPI), exerts preventive effects against OIPN...Notably, esomeprazole, lansoprazole, and rabeprazole, classified as PPIs, prevented oxaliplatin-induced cultured F11 neuronal cell damage, and repeated PPI administration prevented mechanical allodynia in rats. However, vonoprazan, a potassium ion-competitive acid blocker, did not exert such effects. Overall, our results highlight the class effects of PPIs against OIPN."

Journal • Pain

Reevaluating Mega-Dose Esomeprazole in Sepsis: Implications of Comparator Exposure and Comorbidity Imbalance. (PubMed, Crit Care Med) - No abstract available

Journal • Infectious Disease • Septic Shock

Chemoprevention in Barrett's Esophagus: An Updated Review. (PubMed, Gastrointest Endosc Clin N Am) - "Proton pump inhibitors are the cornerstone of chemoprevention, reducing acid reflux, and inflammation, with studies like the Aspirin and Esomeprazole Chemoprevention in Barrett's metaplasia trial suggesting added benefits when combined with aspirin. nonsteroidal antiinflammatory drugs, particularly aspirin, inhibit COX-2, a key enzyme in carcinogenesis, showing promise in reducing EAC risk despite concerns about gastrointestinal bleeding."

Journal • Review • Barrett Esophagus • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroenterology • Gastroesophageal Cancer • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Oncology • Solid Tumor

Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a prospective, multicentre, randomised controlled trial in Gansu Province, a high-resistance region of China. (PubMed, Therap Adv Gastroenterol) - P4 | "Participants were randomised 1:1 to receive either BQT (esomeprazole 20 mg twice daily + bismuth potassium citrate 600 mg twice daily + amoxicillin 1000 mg twice daily + metronidazole 400 mg four times daily) or TA (tegoprazan 50 mg twice daily + amoxicillin 750 mg four times daily) for 14 days. The inferior eradication efficacy of TA precludes its recommendation as a first-line therapy in high-resistance settings, such as Gansu. This trial was registered on the Chinese Clinical Trial Registry with the registration number ChiCTR2400081873."

Journal • Infectious Disease

Drug-induced osteoporosis/osteopenia: a pharmacovigilance analysis using the FDA Adverse Event Reporting System database. (PubMed, Clin Exp Rheumatol) - "This FAERS-based study identified multiple drug classes associated with OP/OPN-related adverse event signals, with anti-viral drugs - particularly tenofovir disoproxil and its combination therapies - exhibiting the strongest signal. Although glucocorticoids had a lower reporting proportion, their short onset time underscores the need for vigilance. These findings provide real-world evidence for drug safety management and highlight the necessity of bone health monitoring in long-term medication users. Future studies should integrate clinical data to validate these findings and explore underlying mechanisms."

Adverse events • Journal • Osteoporosis • Rheumatology

Helicobacter pylori eradication and associated factors: dual therapy versus standard triple therapy in Lima, Peru (PubMed, Rev Gastroenterol Peru) - "The H. pylori eradication rate with dual therapy was superior to standard triple therapy. The proton pump inhibitor with the highest eradication rate was esomeprazole. There were no significant differences in eradication according to sex, age, or comorbidities."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Gastric Cancer • Hypertension • Infectious Disease • Metabolic Disorders • Oncology • Solid Tumor

A Study of Esomeprazole in Children With Autism (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: Stanford University | Suspended ➔ Recruiting | Trial completion date: Mar 2027 ➔ Dec 2028 | Trial primary completion date: Mar 2027 ➔ Dec 2028

Enrollment open • Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders